

Press Release

ATLANTIC THERAPEUTICS RAISES €28 MILLION IN SERIES B

- The FDA product approval has been gained for Atlantic's INNOVO® therapy device to treat incontinence
- Funding facilitates next growth phase, including geographic expansion to US and other markets, new product launches and expanded indications for the INNOVO® therapy platform

Galway, Ireland, January 7th, 2019 – [Atlantic Therapeutics](#), the medical technology company developing garment-based pelvic floor muscle strengthening and nerve stimulation devices treating the cause of bladder leaks, has closed €28 million in Series B funding to continue its rapid growth trajectory.

Having recently gained the Food and Drug Administration (FDA) clearance for its INNOVO® therapy device, this latest round of funding will enable Atlantic Therapeutics to enter the US market, accelerate sales in other geographies, further develop its existing product portfolio, and expand into new clinical applications.

Atlantic Therapeutics' Series B round was led by LSP, one of Europe's largest healthcare investment firms, investing from its LSP Health Economics Fund 2. LSP was joined by Andera Partners, investing from its BioDiscovery 5 fund, and Atlantic Bridge Ventures, investing from the China-Ireland Growth Technology Fund. In addition, the company's existing investors, Seroba Life Sciences and Earlybird Venture Capital, followed their investment.

"INNOVO® has already transformed the lives of many thousands of people in Europe," said Steve Atkinson, CEO of Atlantic Therapeutics. "We are delighted to have completed our Series B financing with such renowned investors and look forward to working together to accelerate the growth and value of Atlantic Therapeutics."

"Atlantic Therapeutics' INNOVO® provides a safe, clinically proven front-line therapy, increasing the options for the treatment of stress urinary incontinence, with the potential to significantly improve quality of life," said Anne Portwich, Partner at LSP. "We are delighted to offer our financial, clinical and commercial support in helping this exciting company grow around the globe."

About Atlantic Therapeutics

Atlantic Therapeutics develops professional and consumer medical devices, related software, apps and connected health technologies to treat all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor. INNOVO® from Atlantic Therapeutics is a unique, externally applied, patented CE device that delivers a safe, clinically effective and comfortable therapy to treat reversible clinical conditions associated with pelvic floor weakness in the comfort of the user's own home. Learn more at: www.restorethefloor.com

About Earlybird

Earlybird is a venture capital investor focused on European technology companies. Founded in 1997, Earlybird invests in all growth and development phases of a company. Amongst the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources, but also strategic and operational support as well as access to an international network and capital markets. Earlybird manages different funds with focuses on digital technologies in Eastern and Western Europe as well as health technologies. With over EUR 1 billion under management, seven IPOs and 23 trade sales, Earlybird is one of the most successful venture capital firms in Europe.

For further information: www.earlybird.com, Twitter: <http://www.twitter.com/EarlybirdVC>. LinkedIn: www.linkedin.com/company/earlybird-venture-capital or Facebook: www.facebook.com/EarlybirdVC

Press Release

Pressekontakt
Earlybird

Catrin Schmidt

+49 30 46 72 47020
press@earlybird.com

Pressekontakt
Atlantic Therapeutics

Paul Jarman (ROAD Communications)

+44 208 995 5832
paul@roadcommunications.co.uk